机构地区:[1]Department of Medicine,Division of Neurology,University of Alberta,Edmonton,Alberta,Canada [2]Department of Internal Medicine,Division of Neurology,University of Manitoba,Winnipeg,Manitoba,Canada [3]Department of Clinical Neurosciences,University of Calgary,Calgary,Alberta,Canada [4]Department of Neurology,University of Miami Miller School of Medicine,Miami,Florida,USA [5]Department of Neurosciences,Radiology and Community Health Sciences,University of Calgary,Calgary,Alberta,Canada [6]Diagnostic and Interventional Neuroradiology,Tours University Hospital,Tours,France [7]Department of Clinical Neurosciences,University of Montreal,Montreal,Québec,Canada [8]Department of Medicine,Queen Elizabeth Health Sciences Centre,Charlottetown,Edward Island,Canada [9]Cumming School of Medicine,University of Calgary,Calgary,Alberta,Canada [10]Department of Medicne,Neurology Division,Sunnybrook Health Sciences Centre,Toronto,Ontario,Canada [11]Department of Medicine,University of Saskatchewan,Saskatoon,Saskatchewan,Canada [12]Kelowna General Hospital,Kelowna,British Columbia,Canada [13]Department of Medicine,Medicine Hat Regional Hospital,Medicine Hat,Alberta,Canada [14]Department of Neurology,University of Toronto,Toronto,Ontario,Canada [15]Department of Neurosciences,University of British Columbia,Vancouver,British Columbia,Canada [16]Department of Medicine,Neurology Division,University of Manitoba,Winnipeg,Manitoba,Canada [17]Department of Medicine,University of Ottawa,Ottawa,Ontario,Canada [18]Division of Neurology,McMaster University,Hamilton,Ontario,Canada [19]Division of Neurology,Sunnybrook Health Sciences Centre,Toronto,Ontario,Canada
出 处:《Stroke & Vascular Neurology》2024年第6期604-612,共9页卒中与血管神经病学(英文)
摘 要:Background In ischaemic stroke,minor deficits(National Institutes of Health Stroke Scale(NIHSS)≤5)at presentation are common but often progress,leaving patients with significant disability.We compared the efficacy and safety of intravenous thrombolysis with tenecteplase versus alteplase in patients who had a minor stroke enrolled in the Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke(AcT)trial.Methods The AcT trial included individuals with ischaemic stroke,aged>18 years,who were eligible for standard-of-care intravenous thrombolysis.Participants were randomly assigned 1:1 to intravenous tenecteplase(0.25 mg/kg)or alteplase(0.9 mg/kg).Patients with minor deficits pre-thrombolysis were included in this post-hoc exploratory analysis.The primary efficacy outcome was the proportion of patients with a modified Rankin Score(mRS)of 0–1 at 90–120 days.Safety outcomes included mortality and symptomatic intracranial haemorrhage(sICH).Results Of the 378 patients enrolled in AcT with an NIHSS of≤5,the median age was 71 years,39.7%were women;194(51.3%)received tenecteplase and 184(48.7%)alteplase.The primary outcome(mRS score 0–1)occurred in 100 participants(51.8%)in the tenecteplase group and 86(47.5%)in the alteplase group(adjusted risk ratio(RR)1.14(95%CI 0.92 to 1.40)).There were no significant differences in the rates of sICH(2.9%in tenecteplase vs 3.3%in alteplase group,unadjusted RR 0.79(0.24 to 2.54))and death within 90 days(5.5%in tenecteplase vs 11%in alteplase group,adjusted HR 0.99(95%CI 0.96 to 1.02)).Conclusion In this post-hoc analysis of patients with minor stroke enrolled in the AcT trial,safety and efficacy outcomes with tenecteplase 0.25 mg/kg were not different from alteplase 0.9 mg/kg.
分 类 号:R743.3[医药卫生—神经病学与精神病学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...